summarized stringlengths 41 385 |
|---|
Primary central nervous system lymphoma (PCNSL) rare lymphoma central nervous system, usually diffuse large B cell phenotype . Stereotactic biopsy followed histopathology diagnostic standard . However, limited material available CNS biopsies |
We pooled data eight nested case-control studies investigate subtype-specific relationships analytes . Using polytomous regression, calculated odds ratios (ORs) 95% confidence intervals (CIs) relating study-specific analyte tertiles |
Chimeric antigen receptor (CAR)-T cell therapy T cell malignancies faces major challenges including fratricide CAR-T cells product contamination blasts . Allogeneic CAR-T cells, generated healthy donor T cells, provide |
Lisocabtagene maraleucel (liso-cel) shown promising efficacy clinical trials . We present health-related quality life (HRQOL) results TRANSFORM study, first comparative analysis liso-cel vs standard |
The testis may infiltrated hematological neoplasias, but entities present primary testicular diseases . According data, testis mainly involved diffuse large B‑cell lymphomas (~70% cases) |
Non-Hodgkin's lymphoma (NHL) monoclonal proliferation lymphoid cells B lineage . 29-year-old female patient presented low-grade fever, cough, anemia, weight loss, tender left |
Axicabtagene ciloleucel (axi-cel) tisagenleclecleucel (tisa-cel) demonstrated impressive clinical activity relapsed/refractory (R/R) diffuse large |
Central nervous system (CNS) lymphomas (CNSLs) varied clinical presentations mimic neuroinflammatory disease . This report describes two patients initially received diagnosis neuroinflammatory disorders refractory treatment protracted time course . |
The Food Drug Administration approved lisocabtagene maraleucel (Breyanzi) Treat large B-cell lymphoma adults relapsed refractory first-line treatment . |
Cyin-dependent protein kinase 6 (CDK6) expression diffuse large B-cell lymphoma (DLBCL) expression . CDK6 alterations DLBCL related functional networks analyzed c-BioPortal Gene Set En |
We aimed compare prognostic predictive ability current clinical scoring indices DLBCL elderly patients treated R-CODP regimen (rituximab, cyclophosphamide, pegylated liposomal doxorubicin, |
Six cases lineage switch lymphoma myeloid neoplasms . Lymphoma relapse common clinical work, lineage switch relapse rare . |
In treatment primary central nervous system lymphoma (PCNSL) intraoperative rapid pathological diagnosis dramatically change surgical strategy, accurate diagnostic methods required . In April 2020, adopted intraoperative rapid immunohistochemistry (IHC) addition conventional rapid |
We performed epidemiological survival analysis of 9,143 PI-NHL cases age 18 years identified SEER 18 database period 2000 - 2015 . Totally, 8,568 patients included survival analysis . Cause-specific survival (CSS) overall survival |
Secondary CNS lymphoma (SCNSL) lacks clear standard care historically carries poor prognosis . Aggressive histologies predominate, notably diffuse large B cell lymphoma (DLBCL) and Burkitt lymphoma lower absolute incidence |
Conditioning chemotherapy (CCT) shown essential optimal efficacy chimeric antigen receptor (CAR) T-cell therapy . 86 (50%) received bridging therapy post-leukapheresis . Median DLIx 0.5 × |
Cytomegalovirus (CMV) among common viral infections solid organ transplantation (SOT) Authors used linked data US SOT registry 32 cancer registries . Poisson regression used compare cancer incidence across CMV risk groups |
Treatment relapsed/refractory diffuse large B-cell lymphoma remains challenge . Treatment relapsed/refractory diffuse large B-cell lymphoma remains challenge . |
Bruton tyrosine kinase inhibitors (BTKis) interrupt B-cell receptor signaling thereby could potentially reactivate hepatitis B virus (HBV) However, data risk HBV reactivation (HBVr) was sparse |
Secondary haemophagocytic lymphohistiocytosis (sHLH) life-threatening disorder described setting infections, neoplastic immune dysregulations . |
Study looked at specific β-glucan, exopolysaccharide (EPS-1) derived Aureobasidium pullulans (CGMCC 20363) The study compared rituximab alone, EPS |
Anthracycline-induced cardiotoxicity irreversible cardiac cell injury . This study designed analyze influencing factors AISC patients diffuse large B-cell lymphoma (DLBCL) treated (R)-CHOP chemotherapy regimen . |
The combination rituximab, lenalidomide, Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib, followed chemotherapy, shown high efficacy patients newly diagnosed diffuse large B-cell |
Axicabtagene ciloleucel treatment. Rapid immune context changes occur tumor microenvironment axicabtagene ciloleucel treatment. Rapid immune context changes occur tumor microenvironment axicabtagene cil |
The objective retrospective study evaluate CD25 expression prognostic indicator dogs B-cell lymphoma (BCL) diagnosed commonly used noninvasive diagnostics (cytology flow cytometry [FC] treated CHOP chemotherapy) Lymph node |
Diffuse large B-cell lymphoma (DLBCL) rare disease crude annual incidence rate 3.8 cases per 100,000 people . Primary cervical lymphoma rare, accounting 0.008% cervical malignancies . |
Data Surveillance, Epidemiology, End Results (SEER) 2000-2018 utilized develop epidemiological model . Model . Estimates DLBCL prevalence gauge impact rapidly emerging treatment landscape . |
The frequency aggressive subtypes B-cell non-Hodgkin lymphoma (B-NHL) are B-NHL, high-grade B-cell lymphomas (HGBL) MYC BCL2 and |
Diffuse large B cell lymphoma (DLBCL) common type NHL, accounting 40% NHL cases, one aggressive lymphomas . DLBCL widespread individuals aged 50 years old, maximum incidence seventh decade, may also occur younger patients |
40% patients with diffuse large B cell lymphoma (DLBCL) experienced relapse refractory (R/R) lymphoma standard first R-CHOP therapy . IL-6 reportedly associated chemotherapy resistance rituximab |
Foreign body-type giant cell reaction typically biological immunological reaction typically biological immunological reaction . |
The effectiveness of comprehensive geriatric assessment (CGA) improving health outcomes cancer settings is unclear . We evaluated whether CGA improve health-related quality life (HRQOL) older people cancer starting anticancer treatment . |
The optimal treatment older adults diffuse large B-cell lymphoma (DLBCL) needs explored due patient comorbidities, standard immunochemotherapy intolerance, unfavourable genetic features . We phase 2 trial ibrutinib |
Chimeric antigen receptor (CAR)-T cell therapy revolutionized treatment hematologic malignancies . Half patients refractory large B cell lymphomas achieve durable responses CD19-targeting CAR-T treatment . Failure mechanisms identified |
Primary central nervous system lymphoma (PCNSL) rare aggressive extranodal diffuse large B cell lymphoma . Despite apparent immunopathological homogeneity, PCNSL displays wide variability outcome . |
This study aimed analyze clinical features survival primary small intestinal diffuse large B-cell lymphoma (PsI-DLBCL) It established independently validate prognostic nomogram individual risk prediction . Data 24 patients Renmin Hospital Wuhan University |
500 patients simulated using distributions metabolic tumor volume, standardized uptake value, maximal distance largest lesion another lesion another lesion, WHO performance status age age . These data used predict progression 2 years based existing logistic regression model . Using simulated |
Diffuse large B-cell lymphoma (DLBCL) common adults' non-Hodgkin's lymphoma . Relapse mainly occurs within two years diagnosis poor prognosis . Relapse two years less frequent better prognosis |
We aimed detect clinicopathological features immune microenvironment double-hit/triple-hit lymphoma gastrointestinal tract (GI-DHL/THL) identify best diagnostic strategies . A total 114 cases, including 15 GI-DHL |
Primary diffuse large B-cell lymphoma (DLBCL) central nervous system (PCNSL) rare disorder increasing incidence past decades . MATRix regimen (high-dose methotrexate (HD-MTX), high |
A large amount of evidence accumulated suggesting Toll-like receptor (TLR) signals involved driving chronic lymphocytic leukemia (CLL) cell proliferation . Direct vivo evidence still lacking . We addressed possibility pharmacologically inhibiting genetically inactivating |
CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) showed poor prognosis rituximab era, limited research genetic characteristics cell origin (COO) We aimed demonstrate molecular characteristics CD5 |
Plasmablastic lymphoma (PBL) is highly aggressive B cell non-Hodgkin lymphoma . PBL is associated with immunosuppression, particularly human immunodeficiency virus (HIV) infection . |
Patients lymphoma also infected Hepatitis B virus (HBV) poor prognosis . This could partly explained delay premature termination anti-tumor treatment HBV reactivation . |
Tumor Tumor Tumor Tumor Tumor Tumor Tumor Tumor Tumor Tumor Tumor Tumor Tumor Tumor Tumor Tum |
The cardiac localization metastases rare condition, often found autopsy . Lymphoma among primary cancers often involved, case patient cardiac involvements discovered extension assessment imaging . |
Diffuse large B-cell lymphoma originates B lymphocytes fatal hematological malignancy . Circular RNAs increasingly reported promising biological target cancer therapy . Role DLBCL remains poorly studied . |
Aryl hydrocarbon receptor-interacting protein (AIP) co-chaperone heat shock proteins nuclear receptors . Loss-of-function heterozygote germline mutations lead predisposition growth hormone- prolactin-secre |
Methotrexate-associated lymphoproliferative disorder (MTX-LPD) occurs patients rheumatoid arthritis (RA) treated methotrexate (MTX) MTX-LPD typically associated Epstein- |
Red blood cell distribution width (RDW) reported associated clinical outcomes multiple cancer . However, prognostic role PCNS-DLBCL yet evaluated . |
Syncope may many different causes, requiring careful identification . Syncope may many different causes, requiring careful identification . Head neck tumors involving carotid artery cause syncope associate carotid sinus syndrome . Syncope may early sole sign |
Pulmonary infections account large proportion of life-threatening adverse events occur chemotherapy patients diffuse large B-cell lymphoma (DLBCL) |
Chimeric antigen receptor T cell (CAR-T) therapy emerged highly effective relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) 40% patients achieved sustained responses . |
Diffuse large B-cell lymphoma (DLBCL) highly aggressive form non-Hodgkin lymphoma . Long noncoding RNA (lncRNA) evaluated prognostic markers various carcinomas . |
Eukaryotic translation initiation factor (eIF) 4A plays essential role unwinding secondary structure messenger RNA (mRNA) upstream start codon . It actively pursued viable target circumvents dependency oncogenic signaling, significant factor |
Double-hit lymphoma (DHL) aggressive large B cell lymphoma associated poor prognosis R-CHOP chemotherapy . The optimal treatment unknown, outcomes might improved intensive induction regimens consolidative high-dose chemotherapy autologous stem |
Burkitt lymphoma (BL) concept high-grade B-cell lymphomas (HGBCL) allows degree refinement . BL remains prototypic HGBCL diagnostic criteria largely unchanged . HGBCL MYC BCL2 HG |
SET MYND domain containing 3 (SMYD3) HMT upregulated various tumors promotes malignancy . High SMYD3 expression significantly associated poor progression-free survival patients DLBCL . |
Diffuse large B-cell lymphoma (DLBCL) common type non- Hodgkin’s lymphoma (NHL) However, primary skeletal muscle involvement DLBCL extremely rare, comprising less 1% extranod |
Epigenetic modifications contribute lymphomagenesis . EC1 presented abundant TP53, MYD88, HIST1H1D, HIST1H1C, KMT2D EZH2 mutations inferior prognosis |
CNS relapse brain parenchyma, eyes, leptomeninges uncommon complication diffuse large B-cell lymphoma . CNS relapse brain parenchyma, eyes, leptomeninges uncommon devastating complication diffuse large B- |
Non-Hodgkin lymphoma (NHL) composed heterogeneous collection subtypes considerable differences genetics, biology aetiology . We pooled data nine case-control studies examine association moderate-to-vigorous intensity physical activity |
Apatinib (an inhibitor targeting VEGFR-2) enhances chemosensitivity ABT-199 diffuse large B-cell lymphoma (DLBCL) Apatinib (an inhibitor targeting VEGFR-2) enhances |
Hypeptics imaging-based approach may help diagnosis diffuse large B-cell lymphoma (DLBCL) Study looked at 22 pathological DLBCL specimens . |
MYD88 oncogene activates nuclear factor κB pathway in DLBCL . Ten MYD88 mutated variants detected 32% of cases . MYD88 L265P mutation frequently occurs DLBCL poor prognosis, clinical |
MALT lymphoma extremely rarely arise extrahepatic biliary tract . Here, report case bile duct MALT lymphoma diagnosed direct cholangioscopy . |
Contrast-enhanced ultrasonography (CEUS) plus D-dimer levels prognosis patients diffuse large B-cell lymphoma (DLBCL) was studied . 186 patients confirmed DLBCL . |
Bromo- Extra-Terminal domain (BET) family proteins strong preclinical antitumor activity multiple tumor models, including lymphomas . Limited single-agent activity reported clinical setting. |
We investigated prevalence prognostic value surface expression PD-L1, PD1, CD30, copy number 9p24.1 (PD-L1 region) mutations . We investigated prevalence prognostic value surface expression PD-L1 |
Diffuse large B-cell lymphoma (DLBCL) characterized strong biological, morphological, clinical . heterogeneity, patients treated immunochemotherapy relatively homogeneous way . NanoString platform analyzed series 197 homogeneously treated DLBCL |
Low lymphocyte-to-monocyte-ratio (LMR) associated unfavorable survival patients diffuse large B-cell lymphoma (DLBCL) To date, however, impact LMR survival has not been seen . |
Diffuse large B-cell lymphoma (DLBCL) is common type non-Hodgkin lymphoma . DLBCL is a common type non-Hodgkin lymphoma . |
Pola-R-CHOP trial showed improved progression-free survival (PFS) compared R-CHOP untreated intermediate- high-risk DLBCL . Of 174 respondents, academic centers (82%) United States (57%) |
NK cells could potentially promote tumour immune evasion disease propagation . NK cells isolated peripheral blood (PB) 26 DLBCL patients 13 age-ma . |
Tisagenlecleucel demonstrated high response rates . Adults relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) was studied in JULIET trial . However, lack response CAR |
Aggressive large B-cell lymphoma (LBCL) variable outcomes . Current prognostic tools use factors risk stratification inadequately identify patients high risk refractory disease relapse initial treatment . |
Diffuse large B-cell lymphoma (DLBCL) common invasive type non-Hodgkin lymphoma . Primary drug resistance treatment DLBCL observed. Primary drug resistance treatment DLBCL observed. |
Axicabtagene ciloleucel (axi-cel) anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved relapsed/refractory large B cell lymphoma (LBCL) |
Several single nucleotide polymorphisms (SNPs) associated susceptibility Hodgkin lymphoma (HL) diffuse large B-cell lymphoma (DLBCL) identified . Aim study identify susceptibility loci HL DLBCL Polish patients . |
The study was published in the journal Human Evolution . |
Despite favorable results CAR T-cell therapy relapsed/refractory large B-cell lymphoma (R/R LBCL) challenges remain . We delineated relative clinical benefit novel approaches compared currently approved CAR T-cell therapies |
HLH 242 patients malignancies-related lymphoid malignancies (42.0%, 233/555) common causes . Epstein-Barr virus (69.0%, 100/145) common pathogen among cases infections- |
CAR-T cell therapy promising effects, patients resistant treatment, leaving limited options . We retrospectively studied three R/R diffuse large B-cell lymphoma patients resistant CAR-T cell therapy . |
There limited published data clinical characteristics outcomes patient population . The outcomes patients i were diagnosed lymphoma following immunosuppressive therapy autoimmune conditions . |
Hepatitis E virus (HEV) infection immunocompetent patients lead chronic hepatitis liver failure . However, burden HEV infection cancer patients largely unknown . We studied characteristics HEV infection patients tertiary care cancer center United States |
Diffuse large B-cell lymphoma (DLBCL) patients reported cardiac manifestations . 11% of DLBCL patients diagnosis arrhythmias . 11% DLBCL patients diagnosis arrhythmias . |
32 immunocompetent patients biopsy-proven diffuse large B-cell type lymphoma brain evaluated pre-treatment MRI examinations August 2014 April 2020 . |
The prediction primary treatment failure (PTF) necessary patients diffuse large B-cell lymphoma (DLBCL) since serves prominent means improving front-line outcomes . The final model contrastive objective optimization, named contrastive hybrid learning model |
Bruton tyrosine kinase inhibitors (BTKi) transformed therapeutic landscape chronic lymphocytic leukaemia (CLL) non-Hodgkin lymphoma . Primary acquired resistance BTKi seen due variety mechanisms including |
The management large malignant tracheo-esophageal fistulas (TEF) standardized. Herein, report case malignant TEF associated esophageal post-transplant lymphoproliferative disorder (PT |
Rituximab become standard treatment non-Hodgkin lymphoma . Clinical studies demonstrated efficacy rituximab combination standard chemotherapies treatment follicular lymphoma (FL) diffuse large B cell lymphoma ( |
Intussusception adults rare occurrence approximately 5% malignancy cause comprises half number . The management adult intussusception generally surgical, due higher likelihood malignancy underlying cause . |
De novo CD5 + diffuse large B-cell lymphoma (DLBCL) poor survival era immunochemotherapy . De novo CD5 + diffuse large B-cell lymphoma (DLBCL) poor survival era immun |
Classic Hodgkin lymphoma (CHL) patients may infrequently present prior recurrent disease discordant histology resembling non-Hodgkin lymphomas . These include primary mediastinal large B-cell lymphoma (PMBL) |
Swedish Lymphoma register 2007-2014 followed relapse death using multistate models study patient trajectories . Achieving lasting remission at 2 years good indicator favourable prognosis long term Diffuse large B-cell lymphoma (DLBC |
Epcoritamab CD3xCD20 bispecific antibody (bsAb) induces T-cell-mediated cytotoxicity CD20-positive B cells . Target engagement crosslinking CD3 CD20 (trimer formation |
Human epidermal growth factor receptor 2 (HER2)-targeted treatment options, including dual HER2 blockade, improved prognosis patients HER2-positive breast cancer (BC) Patients HER2-positive breast cancer (BC) present |
Transesophageal ultrasound-guided bronchoscopic aspiration (EUS-B-FNA) allowed minimally invasive simultaneous diagnosis evaluation degree invasion echocardiography . EUS-B-FNA may useful evaluation diagnosis |
Jaundice caused wide variety disorders adults including pancreatic malignancy . Most pancreatic malignancies primary origin . However, malignancies, including lymphomas, may present secondary pancreatic masses . |
Diffuse large B-cell lymphoma (DLBCL) prevalent subtype non-Hodgkin's lymphoma (NHL) This subtype present various extranodal sites, including brain, bones, intestines |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.